[New features of pharmacologic treatment of erectile dysfunction].
OBJECTIVE
The present article summarizes the latest advancements in the physiology of erection, with special reference to the role of the adenylate and guanylate cyclase-nitric oxide system.


RESULTS
New aspects in the pharmacological intracavernous treatment of erectile dysfunction are discussed and new drugs in this field are analyzed, such as nitrovasodilators, calcium channel blocker, potassium channel openers, phosphodiesterase inhibitors and the combination of adenylate cyclase stimulators.


CONCLUSIONS
A high percentage of patients with erectile dysfunction depends on intracavernous injection of vasoactive drugs for erection. However, this route of administration is painful and causes anxiety in many cases. Other routes of administration (oral, topical or intraurethral) have yet to be developed, as well as drugs that can diminish penile venous blood outflow in cases with venous leakage, and can enhance arterial blood supply at the same time. The combination of phosphodiesterase inhibitors with adenylate and/or guanylate cyclase stimulators or potassium channel openers may further enhance the results achieved to date.
Martínez-Piñeiro
L
L
Servicio de Urología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Espańa.
Galicia de Pedro
I
I
Cisneros
J
J
Cuervo
E
E
Frías Iniesta
J
J
Martínez-Piñeiro
J A
JA
D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010410:Penile Erection / Q000502:physiology
Nuevos aspectos en el tratamiento farmacológico de la disfunción eréctil.